Pancreatic cancer patients who underwent chemotherapy both before and after surgery had longer survival rates compared to those who received...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 25/Jun 12:37
Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation. The study, highlighting a potential breakthrough in personalised cancer treatment, was [...]
Articles similaires
Modified form of chemotherapy before and after surgery enhances survival in pancreatic cancer patients
news.medical.net - 20/Jun 18:31
Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from...
PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer
drugs.com - 27/Jun 15:06
THURSDAY, June 27, 2024 -- PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor...
New global research aims to improve survival rates for pancreatic cancer patients
oncologynews.com.au - 26/Jun 15:44
A new study published in JAMA Network Open by an international cohort of researchers provides the latest data on the effectiveness of treating...
Combo Drug Boosts Survival in Some Women With Early Breast Cancer
drugs.com - 28/Jun 11:47
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...
Combo Drug, Kadcyla, Boosts Survival in Some Women With Early Breast Cancer
drugs.com - 28/Jun 11:06
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...
Kadcyla Boosts Survival in Some Women With Early Breast Cancer
drugs.com - 28/Jun 11:06
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...
Metabolic Signatures Help Predict Cancer Outcomes
medindia.net - 29/Jun 19:41
Researchers have discovered metabolic markers that forecast cancer patients' immunotherapy responses and survival outcomes, highlighting the...
PharmAust raises cash for anti-cancer study
aumanufacturing.com.au - 23/Jun 16:07
Clinical stage biotechnology company PharmAust has received commitments to raise $10 million via an institutional placement with directors and...
JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer
news.medical.net - 22/Jun 03:07
Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung...
Les derniers communiqués
-
Aucun élément